Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study.
berberine
free androgen index
metformin
myo-inositol
polycystic ovary syndrome (pcos)
serum fasting insulin
sex hormone binding globulin
waist circumference
waist hip ratio
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
31
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
This study was conducted to see the effects of berberine, metformin, and myoinositol in women with polycystic ovary syndrome (PCOS). Subjects were randomly assigned via computer-generated randomization to one of the three treatment groups. Group 1 received berberine hydrochloride 500 mg twice daily, group 2 received metformin hydrochloride 500 mg twice daily, and group 3 received myoinositol 1000 mg twice daily to compare clinically (mean weight, waist circumference, waist-to-hip ratio, and body mass index), metabolic (fasting blood sugar, serum fasting insulin, fasting blood sugar/serum fasting insulin [FBS/FI]), hormonal effects (serum total testosterone [TT], serum sex hormone-binding globulin [SHBG] and free androgen index) together with the lipid profile (total cholesterol, serum triglyceride, serum low-density lipoprotein [LDL], very-low-density lipoprotein [VLDL], serum high-density lipoprotein [HDL]) in patients receiving metformin, berberine, and myoinositol before and after three months of treatment. Weight, BMI, waist circumference, waist-hip ratio, FBS, FI and fasting glucose/insulin ratio, total testosterone, free androgen index (FAI), SHBG, total cholesterol, triglycerides, LDL, VLDL, and HDL showed significant differences in three groups after three months of treatment (p<0.0001). Between the three groups, berberine showed greater differences in clinical, hormonal, and lipid parameters compared to metformin and myoinositol, while myoinositol showed greater improvement in carbohydrate metabolic parameters. Metformin, the classical drug used in PCOS, improves all the parameters in polycystic ovary syndrome women. Berberine may have greater potential to reduce the risk of cardiovascular disease than metformin in PCOS patients due to its effect on body composition, lipid profile, and improvement in hormone status. Myoinositol administration improves endocrine parameters and insulin sensitivity. It may be considered as a first-line option in PCOS patients with insulin resistance without prediabetes or diabetes.
Identifiants
pubmed: 35251851
doi: 10.7759/cureus.21781
pmc: PMC8890747
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e21781Informations de copyright
Copyright © 2022, Mishra et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cureus. 2021 Oct 6;13(10):e18553
pubmed: 34754696
Indian J Endocrinol Metab. 2011 Oct;15(4):239-41
pubmed: 22028993
Eur Rev Med Pharmacol Sci. 2021 Apr;25(7):3105-3115
pubmed: 33877679
Clin Diabetes. 2019 Jul;37(3):234-241
pubmed: 31371854
Theranostics. 2019 Mar 16;9(7):1923-1951
pubmed: 31037148
Hum Reprod. 2017 Feb;32(2):261-264
pubmed: 28119448
Gynecol Endocrinol. 2008 Mar;24(3):139-44
pubmed: 18335328
Evid Based Complement Alternat Med. 2019 Dec 13;2019:7918631
pubmed: 31915452
Int J Womens Health. 2011 Feb 08;3:25-35
pubmed: 21339935
Phytomedicine. 2021 Oct;91:153654
pubmed: 34333328
Eur J Endocrinol. 2012 Jan;166(1):99-105
pubmed: 22019891
Evid Based Complement Alternat Med. 2018 Nov 14;2018:2532935
pubmed: 30538756
J Med Life. 2015 Apr-Jun;8(2):187-92
pubmed: 25866577
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616